What is aleniglipron, and is it another Ozempic pill?
Aleniglipron is an experimental once-daily weight-loss pill from Structure Therapeutics. It is not approved or available anywhere, and it is not Ozempic. It entered final-stage Phase 3 trials in July 2026, so results are years away, and every weight-loss figure published so far comes from company press releases, not peer-reviewed studies.
If you keep seeing new weight-loss pills in the news, aleniglipron is one of the names driving the excitement. It is real, it is advancing fast, and the early company figures look strong. It is also not something you can take, and the numbers you have read have not yet been checked by anyone outside the company that makes it.
This article explains what aleniglipron is, where it sits next to Foundayo and the familiar injections, what the published figures actually say, and why "promising" and "available" are not the same thing. Nothing here is a reason to seek out or wait for an unapproved drug.
What is aleniglipron?
Aleniglipron is an investigational once-daily pill that mimics the gut hormone GLP-1, the same hormone targeted by Ozempic and Wegovy. Its development code is GSBR-1290, and it is made by Structure Therapeutics, with its trials run through a subsidiary called Gasherbrum Bio.3 Aleniglipron is a small molecule rather than a peptide, which is what lets it work as a swallowed tablet instead of an injection.4
Aleniglipron is being developed for chronic weight management in adults with obesity or overweight, including people who also have type 2 diabetes.12 It is taken by mouth once a day, with the dose raised gradually, the same way the familiar injectable GLP-1 drugs are started slowly to limit side effects.
Is it another Ozempic pill like Foundayo?
Not exactly. Aleniglipron sits in the newest group of GLP-1 drugs: oral small-molecule pills. The first drug of that type to reach the market was Foundayo (orforglipron) from Eli Lilly, and aleniglipron is one of the next candidates in the same class.4 You can see how that first pill performed in our guide to how much weight people lose on Foundayo, and where every current oral option fits in our look at how many GLP-1 pills there are now.
Aleniglipron is not semaglutide, the drug inside Ozempic and Wegovy, and it is not the oral semaglutide sold as Rybelsus, which is a peptide that needs a special additive to survive the stomach. Aleniglipron is a different molecule designed from the start to be a stable, non-peptide tablet. So "another Ozempic pill" is a useful shorthand for the search box, but the honest answer is that aleniglipron is a separate drug aiming at the same target.
Where is aleniglipron in development?
Aleniglipron recently reached the final stage of testing before any approval decision. Two pivotal Phase 3 trials, ACCOMPLISH-1 and ACCOMPLISH-2, began recruiting in July 2026.12 ACCOMPLISH-1 plans to enrol about 3,600 adults with obesity or overweight and a weight-related health problem, and ACCOMPLISH-2 plans about 1,100 adults who also have type 2 diabetes.12 Both compare the pill against a placebo and measure how much body weight changes.
Neither Phase 3 trial is expected to reach its main results before about September 2028.12 Four earlier Phase 2 trials, including the dose-finding study called ACCESS, have already finished.3 Approval, if it comes at all, would follow the Phase 3 results and a regulator's review, which places any real-world availability years away, not months.
How much weight did aleniglipron cause?
This is where honesty matters most. In the Phase 2b ACCESS trial, Structure Therapeutics reported placebo-adjusted average weight loss of 8.2% on the 45 mg dose, 9.8% on 90 mg and 11.3% on the top 120 mg dose after 36 weeks.4 A separate exploratory trial, ACCESS II,5 reported up to 15.3% on a higher 240 mg dose over the same period.4 Across the active doses, about one in ten people stopped the drug because of a side effect, and the most common side effects were gut-related, such as nausea and vomiting while the dose was being raised.4
| Daily dose | Weight loss vs placebo | Trial | Timepoint |
|---|---|---|---|
| 45 mg | 8.2% | ACCESS (Phase 2b) | 36 weeks |
| 90 mg | 9.8% | ACCESS (Phase 2b) | 36 weeks |
| 120 mg | 11.3% | ACCESS (Phase 2b) | 36 weeks |
| 240 mg | 15.3% | ACCESS II (exploratory) | 36 weeks |
Company-announced topline figures from a Structure Therapeutics press release, December 8, 2025.4 These numbers are not peer-reviewed and are not posted on ClinicalTrials.gov.3 Figures are averages; individual results vary.
Every one of those numbers comes from a company press release, not from a peer-reviewed journal.4 The public trial registry still shows no posted results for any aleniglipron study.3 Company topline figures are not invented, but the maker selects and announces them before independent review, so they should be read as early and unconfirmed, not as settled proof.
"A promising press release is a reason to watch a drug, not a reason to wait for it."
Is aleniglipron approved or available?
No. Aleniglipron is not approved by the FDA or any other regulator, it is not sold in any pharmacy, and no doctor can prescribe it outside a clinical trial.1 The only way to take aleniglipron right now is to be enrolled in one of its ongoing studies.
A drug entering Phase 3 is a drug being tested, not a drug that has passed. Candidates with strong Phase 2 numbers can still fail or stall in Phase 3. For anyone managing their weight today, the practical options are the drugs already approved and in use, chosen with a doctor. Aleniglipron is one of several pipeline candidates worth watching, alongside the question of whether a once-a-month GLP-1 injection exists yet.
In one sentence: Aleniglipron is a promising experimental weight-loss pill from Structure Therapeutics that just entered final-stage trials, but it is not approved, not available, and every weight-loss number published so far comes from company press releases rather than peer-reviewed studies.
Frequently asked
Is aleniglipron approved or available to buy?+
Is aleniglipron the same as Ozempic or Foundayo?+
How much weight did aleniglipron cause in trials?+
References
- Gasherbrum Bio, Inc. (a subsidiary of Structure Therapeutics). A Pivotal Phase 3 Study of Oral Once-Daily Aleniglipron for Chronic Weight Management (ACCOMPLISH-1). ClinicalTrials.gov, NCT07654361. Phase 3; randomized, double-blind, placebo-controlled; estimated enrolment 3,600; study start July 13, 2026; estimated primary completion September 2028; aleniglipron versus placebo. No results posted.
- Gasherbrum Bio, Inc. (a subsidiary of Structure Therapeutics). A Phase 3 Study of Oral Once-Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes (ACCOMPLISH-2). ClinicalTrials.gov, NCT07654374. Phase 3; randomized, double-blind, placebo-controlled; estimated enrolment 1,100; study start July 17, 2026; estimated primary completion September 2028; last update posted October 20, 2026. No results posted.
- Gasherbrum Bio, Inc. (a subsidiary of Structure Therapeutics). A Phase 2b, Dose-Range Finding Study of the Efficacy and Safety of Aleniglipron (GSBR-1290) (ACCESS). ClinicalTrials.gov, NCT06693843. Phase 2; completed; actual enrolment 230; actual primary completion October 24, 2025. As of October 2026 the record shows no results section posted.
- Structure Therapeutics Inc. Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron. Press release, December 8, 2025 (U.S. SEC Form 8-K, Exhibit 99.1). Company-announced topline results; not peer-reviewed. Reports placebo-adjusted weight loss of 8.2% (45 mg), 9.8% (90 mg) and 11.3% (120 mg) at 36 weeks in ACCESS, and up to 15.3% (240 mg) in ACCESS II, with adverse-event-related discontinuation averaging about 10.4% across active doses.
- Gasherbrum Bio, Inc. (a subsidiary of Structure Therapeutics). A Phase 2, Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight (ACCESS II). ClinicalTrials.gov, NCT06703021. Phase 2; completed; actual enrolment 85. An exploratory study; as of October 2026 the record shows no results section posted.
Evidence current as of October 26, 2026. This article is educational and not medical advice. Aleniglipron is an investigational drug that is not approved or available; always consult a qualified clinician before starting, stopping or changing a medication.
Translating new metabolic and obesity research into plain English for people living on GLP-1 therapy. Every claim is traced to its source.